Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35 results about "CXCR4 Inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An antagonist of the C-X-C chemokine receptor type 4 (CXCR4). CXCR4, which belongs to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types.
Anti-cxcr4 as a sensitizer to cancer therapeutics
ActiveUS20130216531A1Promote cell survivalPrevent infiltration of tumorBiocidePeptide/protein ingredientsCXCR4CXCR4 Inhibitor
Inhibition of CXCR4 can inhibit tumor growth and metastasis during certain therapeutic windows. Disclosed are novel methods for treating and preventing cancer in a subject related to administration of CXCR4 inhibitors during a therapeutic window following treatment with another anti-tumor therapy.
Owner:THE GENERAL HOSPITAL CORP
Anti-CXCR4 as a sensitizer to cancer therapeutics
ActiveUS9155723B2Prevent infiltrationConducive to survivalBiocidePeptide/protein ingredientsCXCR4CXCR4 Inhibitor
Inhibition of CXCR4 can inhibit tumor growth and metastasis during certain therapeutic windows. Disclosed are novel methods for treating and preventing cancer in a subject related to administration of CXCR4 inhibitors during a therapeutic window following treatment with another anti-tumor therapy.
Owner:THE GENERAL HOSPITAL CORP
Methods for the treatment of multiple myeloma
Methods for treating multiple myeloma with inhibitors of CXCR4, such as AMD3100 and anti-CXCR4 antibodies, are described. The decreased expression of CXCR4 on multiple myeloma cells according to the invention results in decreased homing of the cells to the bone marrow and a reduction in the development of the disease. Also disclosed are pharmaceutical compositions incorporating such inhibitors for use in the therapeutic treatment of multiple myeloma. The treatment methods described herein can be used independently, or in conjunction with, other therapies for the treatment of multiple myeloma.
Owner:IMMUNE DISEASE INST INC
Cxcr4 inhibitors and uses thereof
Owner:X4 PHARMA INC
Cxcr4 inhibitors and uses thereof
Owner:X4 PHARMA INC
Compositions and Methods for Treating Ophthalmic Diseases
This invention relates to CXCR4 inhibitors and their use in treating and / or preventing a variety of angiogenic, microvascular and ocular disorders including primary indications for diabetic retinopathy, macular degeneration (such as wet or neovascular age-related macular degeneration (AMD) and dry or atrophic AMD), macular edema, and secondary indications for inhibiting tumor vascularization, and corneal and iris neovascularization.
Owner:MERCK SHARP & DOHME CORP
Cxcr4 inhibitors and uses thereof
Owner:X4 PHARMA INC
CXCR4 inhibitors and uses thereof
Owner:X4 PHARMA INC
Compositions and methods for treating ophthalmic diseases
InactiveCN101035537ASuppress generationOrganic active ingredientsSenses disorderDiseaseIris neovascularization
This invention relates to CXCR4 inhibitors and their use in treating and / or preventing a variety of angiogenic, microvascular and ocular disorders including primary indications for diabetic retinopathy, macular degeneration (such as wet or neovascular age-related macular degeneration (AMD) and dry or atrophic AMD), macular edema, and secondary indications for inhibiting tumor vascularization, and corneal and iris neovascularization.
Owner:MERCK & CO INC
Cancer serum biomarkers and methods of use thereof
The present invention relates, in part, to certain serum biomarkers and use thereof in methods for treating cancer, such as in evaluating and / or in additional methods such as predicting patient responses to treatment with a CXCR4 inhibitor optionally in combination with a immunotherapeutic agent, in patients with a cancer such as melanoma, including resectable and unresectable melanoma.
Owner:X4 PHARMA INC
Stromal Derived Factor Inhibition And CXCR4 Blockade
The invention relates to inhibition of SDF-1α expression in subacromial bursa cells by CXCR-4 inhibitors. Bursal cell migration in response to SDF-α stimulation is also decreased in the presence of CXCR4 inhibitors. Accordingly, provided are methods for treating or ameliorating a musculoskeletal disorder.
Owner:RHODE ISLAND HOSPITAL
Methods for the treatment of multiple myeloma
Methods for treating multiple myeloma with inhibitors of CXCR4 are described. The decreased expression of CXCR4 on multiple myeloma cells according to the invention results in decreased homing of the cells to the bone marrow and a reduction in the development of the disease. Also disclosed are pharmaceutical compositions incorporating such inhibitors for use in the therapeutic treatment of multiple myeloma. The treatment methods described herein can be used independently, or in conjunction with, other therapies for the treatment of multiple myeloma.
Owner:CENT FOR BLOOD RES
Combination therapy
InactiveCN101495115AAntineoplastic agentsHeterocyclic compound active ingredientsBone marrow metastasisBlood flow
Methods to mobilize progenitor and / or stem cells from the bone marrow to the bloodstream by administering a combination of at least one CXCR4 inhibitor and at least one VLA-4 inhibitor are described. The combinations may also be used to treat multiple myeloma.
Owner:GENZYME CORP
Combination Therapy
InactiveUS20100003224A1Recovery functionEasy to understandBiocidePeptide/protein ingredientsProgenitorVLA-4
Methods to mobilize progenitor and / or stem cells from the bone marrow to the bloodstream by administering a combination of at least one CXCR4 inhibitor and at least one VLA-4 inhibitor are described. The combinations may also be used to treat multiple myeloma.
Owner:GENZYME CORP
Pyridine heterocyclic compound and application thereof serving as CXCR4 inhibitor
ActiveCN110317191APrevention of receptor antagonistic conditionsSenses disorderAntipyreticCXCR4 Signaling PathwayCXCR4 Inhibitor
The invention provides a pyridine heterocyclic compound and application thereof serving as a CXCR4 inhibitor. The structure of the heterocyclic compound and the pharmaceutically acceptable salt, isotope, isomer and crystal form thereof is as shown in general formula I. The heterocyclic compound has CXCR4 signal channel inhibitory activity. The heterocyclic compound with the CXCR4 signal channel inhibitory activity can serve as the effective antagonist of CXCR4 signal channels and can be used for treating or preventing diseases responding to CXCR4 receptor antagonism.
Owner:CGENETECH (SUZHOU CHINA) CO LTD
Combination therapy
Methods to mobilize progenitor and / or stem cells from the bone marrow to the bloodstream by administering a combination of at least one CXCR4 inhibitor, at least one CXCR2 agonist, and G-CSF are described. The combinations may also be used to increase the effectiveness of chemotherapy and radiation therapies for hematopoietic malignancies.
Owner:GENZYME CORP
Methods for the treatment of multiple myeloma
Methods for treating multiple myeloma with inhibitors of CXCR4, such as AMD3100 and anti-CXCR4 antibodies, are described. The decreased expression of CXCR4 on multiple myeloma cells according to the invention results in decreased homing of the cells to the bone marrow and a reduction in the development of the disease. Also disclosed are pharmaceutical compositions incorporating such inhibitors for use in the therapeutic treatment of multiple myeloma. The treatment methods described herein can be used independently, or in conjunction with, other therapies for the treatment of multiple myeloma.
Owner:IMMUNE DISEASE INST INC
4-aminopyrimidine derivative as CXCR4 inhibitor, and applications thereof
ActiveCN109553604AHas inhibitory activityGood drug interaction safetyOrganic active ingredientsSenses disorderDiseaseCXCR4 Signaling Pathway
The present invention provides a heterocyclic compound having CXCR4 signaling pathway inhibitory activity, and a pharmaceutically acceptable salt, an isotope, an isomer and a crystal form structure thereof, wherein the compound has a structure represented by a general formula I defined in the specification. The present invention further provides applications of the heterocyclic compound having CXCR4 signaling pathway inhibitory activity. According to the present invention, the heterocyclic compound having CXCR4 signaling pathway inhibitory activity, as the effective antagonist of the CXCR4 signaling pathway, can be used for treating or preventing diseases responsive to CXCR4 receptor antagonism.
Owner:CGENETECH (SUZHOU CHINA) CO LTD
Method and medicament for inhibiting generation of neonatal lymphatic vessel
The invention provides a method for inhibiting generation of a neonatal lymphatic vessel of a subject, comprising: application of a CXCR4 inhibitor and / or a CXCL12 inhibitor with an effective amount for treating the subject. The invention further provides a method for inhibiting transfer of tumour lymphocyte in a tumour patient, comprising: combined application of (a) a CXCR4 inhibitor and / or CXCL12 inhibitor with an effective amount for treatment, and (b) a VEGF-C inhibitor, and / or a VEGF-D, and / or a VEGFR-3 inhibitor with an effective amount for treatment.
Owner:TSINGHUA UNIV +1
CXCR4 inhibitors and uses thereof
Owner:X4 PHARMA INC
Methods for treating cancer
InactiveCN110996952ADipeptide ingredientsInorganic active ingredientsCXCR4 InhibitorPharmaceutical drug
The present invention relates to methods of treating cancer, in which a CXCR4 inhibitor such as X4P-001 or a pharmaceutically acceptable salt thereof or pharmaceutical composition thereof is administered in combination with an additional therapeutic agent, such as an immune checkpoint inhibitor. The methods demonstrate surprising results, including regression of disease, with comparatively littletoxicity.
Owner:X4 PHARMA INC
4-aminopyrimidine derivatives as cxcr4 inhibitors and their application
ActiveCN109553604BHas inhibitory activityGood drug interaction safetyOrganic active ingredientsSenses disorderCXCR4 Signaling PathwayDisease
Owner:CGENETECH (SUZHOU CHINA) CO LTD
CXCR4 inhibitors and uses thereof
Owner:X4 PHARMA INC
Acyclic cxcr4 inhibitors and uses thereof
The present invention relates to compounds and methods useful for modulation, e.g. inhibition, of C-X-C receptor type 4 (CXCR4). The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using the compositions in the treatment of various disorders.
Owner:X4 PHARMA INC
Method for inhibiting lymphangiogenesis by administration of an inhibitor of the cxcl12 pathway
InactiveUS20180094051A1Effectively inhibit tumor lymphangiogenesis and lymphatic metastasisEffectively inhibit lymphatic metastasisPeptide/protein ingredientsAntipyreticLymphatic vesselCXCR4 Inhibitor
The present invention provides a method for inhibiting lymphangiogenesis in a subject, comprising administering a therapeutically effective amount of a CXCR4 inhibitor and / or a CXCL12 inhibitor to the subject. The invention further provides a method for inhibiting tumor lymphatic metastasis in a cancer patient, comprising administering to the subject (a) a therapeutically effective amount of a CXCR4 inhibitor and / or a CXCL12 inhibitor, in combination with (b) a therapeutically effective amount of a VEGF-C inhibitor and / or a VEGF-D inhibitor and / or a VEGFR-3 inhibitor.
Owner:TSINGHUA UNIV +1
CXCR4 inhibitors and uses thereof
The present invention relates to compounds and methods for inhibiting the C-X-C receptor type 4 (CXCR4). The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Owner:X4 PHARMA INC
Deuterated compounds and uses thereof
PendingUS20220017487A1Easy to useIsotope introduction to heterocyclic compoundsAntineoplastic agentsDiseaseCXCR4
Owner:X4 PHARMA INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com